Gastrointestinal

Chronic pancreatitis: pain and exocrine insufficiency management

Clinical Overview and When to Suspect Chronic Pancreatitis

— Toxic-metabolic: alcohol (~45% of US cases, threshold often >5 drinks/day for >5 years), tobacco (independent, dose-dependent risk factor — often underappreciated)

— Idiopathic (early- and late-onset; ~25%)

— Genetic: PRSS1 (hereditary, autosomal dominant), CFTR, SPINK1, CTRC

— Autoimmune: IgG4-related (type 1) and idiopathic duct-centric (type 2)

— Recurrent/severe acute pancreatitis

— Obstructive: pancreas divisum, stricture, neoplasm, prior trauma

— Recurrent epigastric pain radiating to back in a 40–50 year old with heavy alcohol and smoking history

— Steatorrhea (greasy, foul, floating stools), weight loss, fat-soluble vitamin deficiency (A, D, E, K)

— New diabetes in a thin patient with malabsorption ("type 3c" pancreatogenic diabetes)

— Calcifications on a prior abdominal film/CT in someone with vague chronic upper abdominal pain

Board pearl: A nondiabetic patient who develops diabetes plus steatorrhea plus weight loss should trigger workup for type 3c diabetes from CP or pancreatic cancer — not assumed to be type 2.

Chronic pancreatitis (CP) is a progressive fibroinflammatory disease of the pancreas producing irreversible parenchymal damage, with two hallmark consequences: chronic abdominal pain and loss of exocrine and endocrine function (steatorrhea, diabetes).

Epidemiology and etiology (TIGAR-O framework):

When to suspect on Step 3 vignettes:

Natural history: pain often dominates early, then "burnout" phase with less pain but worsening exocrine/endocrine insufficiency after 5–10 years. Don't be falsely reassured when pain improves — function is still declining.

Increased risk of pancreatic adenocarcinoma (especially hereditary CP — lifetime risk ~40%).

Presentation Patterns and Key History

— Epigastric, often radiating to the back, worse postprandially (food triggers CCK release → pancreatic stimulation)

— Relieved by leaning forward or fetal position

— Episodic early ("type A"), constant/daily later ("type B" — worse prognosis, more disability)

— Often leads to opioid dependence and frequent ED visits — a Step 3 social/biopsychosocial cue

— Steatorrhea: bulky, pale, oily, malodorous stools that float; oil droplets on water

— Unintentional weight loss despite preserved appetite

— Bloating, flatulence, postprandial diarrhea

— Fat-soluble vitamin deficiency: night blindness (A), osteoporosis/osteomalacia (D), neuropathy/hemolysis (E), easy bruising (K)

— Alcohol quantity, duration, current use, prior treatment attempts (CAGE, AUDIT)

— Tobacco pack-years — independent and synergistic with alcohol

— Family history of pancreatitis or pancreatic cancer (genetic etiology)

— Prior episodes of acute pancreatitis (RAP → CP continuum)

— Medications, autoimmune disease (IgG4, Sjögren, IBD → AIP)

— Surgical history (gastric, biliary), trauma

— Functional impact: work, sleep, mood, opioid use

Step 3 management: At the index visit, document tobacco and alcohol use, offer cessation counseling, and schedule structured follow-up — both are independent disease modifiers, and cessation is the single highest-impact intervention you can prescribe for CP progression.

Pain phenotype — the central clinical complaint:

Exocrine insufficiency symptoms (appear when >90% acinar function lost):

Endocrine insufficiency: brittle diabetes with hypoglycemia risk (loss of both insulin and glucagon)

Targeted history must capture:

Red flags suggesting malignancy or alternate diagnosis: rapid weight loss, painless jaundice, palpable mass, new-onset diabetes after 50 with no risk factors, dramatic CA 19-9 elevation.

Physical Exam Findings and Functional Assessment

— Cachexia, temporal wasting, sarcopenia — reflects malabsorption and chronic catabolism

— Skin: jaundice (rare; suggests distal CBD stricture or head mass), ecchymoses (vitamin K deficiency)

— Stigmata of alcohol use: telangiectasias, palmar erythema, parotid enlargement, Dupuytren contractures

— Mild epigastric tenderness without peritoneal signs

— Palpable pseudocyst as an epigastric mass in some cases

— Bruit rare; splenomegaly may indicate splenic vein thrombosis (sinistral portal hypertension)

— Absence of guarding/rebound — peritonitis suggests an alternate acute process

— Proximal weakness, bone tenderness (vitamin D deficiency, osteomalacia)

— Peripheral neuropathy (alcohol, B12, vitamin E)

— Chvostek/Trousseau if hypocalcemia from vitamin D deficiency or steatorrheic Ca²⁺ losses

— Weight and BMI trend — best bedside index of nutritional adequacy

— Grip strength or simple "sit-to-stand" for sarcopenia screen

— Mood screen (PHQ-9) — depression in 30–50%, drives pain perception and opioid use

— Substance use screen at every visit

Key distinction: In acute pancreatitis, exam reveals diffuse tenderness, ileus, and systemic illness. In uncomplicated CP, exam is often bland — pain is neuropathic-visceral, and significant peritoneal signs should prompt search for a complication rather than be attributed to "chronic" disease.

CP often presents with a surprisingly unremarkable abdominal exam, which itself is a clue when pain is severe and out of proportion to findings.

Inspection:

Abdomen:

Neuromusculoskeletal:

Functional/global assessment Step 3 wants you to do:

Vitals usually normal in stable outpatient CP. Tachycardia, fever, or hypotension should redirect to acute-on-chronic pancreatitis, infected pseudocyst, cholangitis, or bleeding pseudoaneurysm.

Diagnostic Workup — Initial Labs and Imaging

— Amylase and lipase are often normal in established CP because of acinar loss — a normal lipase does NOT exclude CP

— CBC, CMP, LFTs (cholestatic pattern → distal CBD stricture or mass)

— HbA1c and fasting glucose at diagnosis and annually — screen for type 3c diabetes

— Fecal elastase-1 (single stool sample): <200 μg/g suggests exocrine insufficiency; <100 μg/g is severe. First-line functional test — easy, no formula change needed

— 72-hour fecal fat (gold standard, rarely used; >7 g/day on 100 g fat diet = steatorrhea)

— Fat-soluble vitamin levels (A, D, E, INR for K), B12, magnesium, zinc, prealbumin

— IgG4 if autoimmune pancreatitis suspected

— CA 19-9 not for routine screening (nonspecific in CP)

— Triglycerides, calcium (rule out hypercalcemic/hypertriglyceridemic etiologies)

— Findings: parenchymal calcifications (pathognomonic when present), main duct dilation, atrophy, pseudocysts

— Rules out malignancy and complications

— Plain film may show calcifications but is not adequate

— MRI/MRCP with secretin enhancement (sMRCP) — best noninvasive look at ductal anatomy; secretin distends ducts and assesses functional reserve

— Visualizes side-branch ectasia (early CP), main duct strictures, "chain of lakes" appearance

Board pearl: Fecal elastase-1 is the right answer when the stem asks how to confirm pancreatic exocrine insufficiency in suspected CP — cheap, noninvasive, and not affected by ongoing enzyme supplementation (unlike fecal chymotrypsin).

Laboratory testing (CP is not diagnosed by amylase/lipase):

Imaging — first line is CT abdomen with pancreas protocol:

If CT is nondiagnostic and suspicion remains:

Genetic testing in young patients (<35), recurrent acute pancreatitis without clear etiology, or strong family history.

Diagnostic Workup — Advanced and Confirmatory Studies

— Parenchymal: hyperechoic foci with shadowing, lobularity, cysts, stranding

— Ductal: main duct dilation, hyperechoic margins, dilated side branches, stones

— ≥5 features = consistent with CP; allows FNA if a mass is identified to exclude adenocarcinoma

— IV secretin stimulates pancreatic secretion; assesses ductal compliance, side-branch filling, and duodenal fluid volume as a surrogate for exocrine function

— Useful when EUS is unavailable or contraindicated

— Type 1 (IgG4-related): elevated serum IgG4 (>2× ULN), diffuse "sausage-shaped" pancreas with rim enhancement, other organ involvement (sclerosing cholangitis, retroperitoneal fibrosis, sialadenitis)

— Type 2 (idiopathic duct-centric): younger patients, associated with IBD, normal IgG4, histologic diagnosis with granulocytic epithelial lesions

— Both respond dramatically to prednisone 40 mg/day taper

Key distinction: A focal mass in a patient with CP must be evaluated as cancer until proven otherwise — EUS-FNA is the test of choice, because background fibrosis can mask or mimic adenocarcinoma on cross-sectional imaging.

When CT and MRCP are equivocal but clinical suspicion is high, escalate to endoscopic ultrasound (EUS) — most sensitive for early CP before calcifications develop.

EUS Rosemont criteria assess parenchymal and ductal features:

Secretin-enhanced MRCP (sMRCP):

ERCP — diagnostic role has largely been replaced by MRCP/EUS due to post-ERCP pancreatitis risk (~5%); reserve for therapeutic indications (stone extraction, stricture stenting, drainage).

Direct pancreatic function tests (secretin or CCK stimulation with duodenal aspiration) — most sensitive functional test for early disease but technically demanding and rarely available; usually only at referral centers.

Autoimmune pancreatitis workup (don't miss — it's reversible with steroids):

Pancreatic biopsy is rarely necessary except to confirm AIP or rule out malignancy when a focal mass is present.

Risk Stratification and Management Logic

— 1. Etiologic modification (alcohol, tobacco, genetic counseling, autoimmune treatment)

— 2. Pain control (stepwise, multimodal, opioid-sparing)

— 3. Exocrine insufficiency (PERT, nutrition, vitamins)

— 4. Endocrine insufficiency (diabetes screening and treatment)

— Plus surveillance for complications and malignancy

— Complete alcohol abstinence — reduces pain frequency, slows progression, decreases mortality. Refer to AA, naltrexone, acamprosate as appropriate

— Tobacco cessation — independently slows calcification and reduces cancer risk; varenicline, NRT, bupropion

— Dietary: small, frequent, moderate-fat meals (not low-fat — fat needed for caloric intake and vitamin absorption); avoid fasting and binge meals that trigger pain

— Daily opioid use >3 months

— Inability to work or maintain weight

— Dilated main pancreatic duct (>6 mm) — good surgical candidate for drainage procedure

— Inflammatory mass, suspicious lesion, or recurrent pseudocyst

Step 3 management: At diagnosis, document a written longitudinal plan that includes cessation counseling, baseline DEXA and HbA1c, fecal elastase, fat-soluble vitamin panel, and a return visit in 4–8 weeks. Boards reward the candidate who treats CP as a chronic disease bundle, not a single-symptom problem.

Once CP is established, structure management around four parallel tracks that you address at every visit — Step 3 loves this kind of longitudinal framework:

Behavioral foundations (must be addressed first; non-negotiable):

Risk stratification for advanced/refractory disease (triggers for surgical referral):

Multidisciplinary team: gastroenterology, pain medicine, nutrition, endocrinology, addiction medicine, behavioral health, surgery.

Pharmacotherapy — Pain and Exocrine Insufficiency

— Step 1: Acetaminophen up to 3 g/day; NSAIDs (caution: GI/renal); avoid in active alcohol use

— Step 2: Adjuvant neuromodulators — pregabalin is the best-evidenced (RCT-supported reduction in CP pain); gabapentin, TCAs (amitriptyline, nortriptyline), or SNRIs (duloxetine) for visceral hyperalgesia

— Step 3: Tramadol preferred over traditional opioids — equal efficacy with less constipation and dependence

— Step 4: Short-acting opioids only after multimodal failure; avoid long-acting opioids if possible. Co-prescribe a bowel regimen and naloxone. Use a single-prescriber pain agreement

— Antioxidant therapy (selenium, vitamin C, β-carotene, methionine): modest pain benefit in some trials, low cost, reasonable adjunct

— Pancreatic enzymes for pain: weak evidence; non–enteric-coated preparations theoretically suppress CCK feedback — try in small-duct disease

— Celiac plexus block (EUS-guided): temporary relief (~3–6 months), useful bridge

— Indicated for fecal elastase <100, or 100–200 with symptoms, or clinical steatorrhea/weight loss

— Dosing: 40,000–50,000 USP lipase units with each main meal, half-dose with snacks

— Take with the first bite; if eating a long meal, split dose

— Use enteric-coated mini-microspheres to survive gastric acid

— If inadequate response: first increase the dose, then add a PPI to prevent acid inactivation of enzymes

— Monitor: weight gain, resolution of steatorrhea, normalization of fat-soluble vitamins

Board pearl: If PERT is failing, the next step is dose escalation, then add a PPI — not switching brand. Persistent symptoms despite high-dose PERT + PPI should trigger evaluation for SIBO (treat with rifaximin).

Pain — stepwise approach (analogous to WHO ladder, but with CP-specific twists):

Exocrine insufficiency — pancreatic enzyme replacement therapy (PERT):

Vitamin replacement: A, D, E, K, B12, calcium; DEXA scan at baseline and every 2 years.

Procedures and Invasive Management

— Main pancreatic duct stones: extracorporeal shock wave lithotripsy (ESWL) ± ERCP extraction

— Dominant strictures: balloon dilation and stenting (sequential upsizing over 6–12 months)

— Pseudocyst drainage: EUS-guided transmural drainage with lumen-apposing metal stents (LAMS) preferred when adjacent to stomach/duodenum

— Celiac plexus block/neurolysis: EUS-guided, for refractory pain

— Dilated main duct (>6–7 mm): lateral pancreaticojejunostomy (Puestow procedure) — drainage operation, preserves parenchyma

— Inflammatory head mass: Frey (combined drainage + local head resection) or Beger (duodenum-preserving head resection)

— Whipple (pancreaticoduodenectomy): reserved for head-dominant disease with suspicion for malignancy

— Distal pancreatectomy: tail-predominant disease

— Last resort for diffuse small-duct disease with intractable pain, especially in hereditary CP (PRSS1)

— Pancreas removed, islet cells isolated and infused into the portal vein

— Reduces pain but produces brittle diabetes (~30% remain insulin-independent)

— Splenic vein thrombosis with bleeding gastric varices → splenectomy

— Pancreatic ascites/fistula → octreotide, ERCP stent, then surgery if refractory

— Pseudoaneurysm (splenic, gastroduodenal) → angiographic embolization first

CCS pearl: For a CP patient admitted with bleeding from gastric varices and isolated splenic vein thrombosis on CT, order surgical consult for splenectomy — anticoagulation is generally avoided, and splenectomy is curative for sinistral portal hypertension.

Endoscopic therapy (ERCP) — first-line for anatomically favorable disease:

Surgical therapy — consider when endoscopic therapy fails or anatomy is unfavorable; earlier surgery may offer better pain outcomes than prolonged endotherapy (ESCAPE trial):

Total pancreatectomy with islet autotransplantation (TPIAT):

Complication-directed procedures:

Special Populations — Elderly, Renal, and Hepatic Impairment

— New-onset "CP-like" pain or pancreatic insufficiency after age 60 should prompt aggressive workup for pancreatic adenocarcinoma before accepting CP diagnosis — EUS with FNA of any mass

— Increased risk of opioid-related falls, delirium, constipation; avoid long-acting opioids and TCAs (anticholinergic load)

— Pregabalin: start low (25–50 mg BID), titrate slowly; dose-adjust for CrCl

— Higher osteoporosis risk — DEXA, calcium, vitamin D essential

— Polypharmacy review; deprescribe PPIs only after confirming PERT efficacy doesn't depend on them

— Pregabalin and gabapentin are renally cleared — reduce doses (pregabalin ~75 mg/day for CrCl 30–60; lower for worse)

— NSAIDs contraindicated in CKD stage ≥3

— Tramadol accumulates in renal failure → seizure risk; reduce dose

— Avoid magnesium-containing antacids

— PERT itself is safe in CKD; lipase units are not renally cleared

— Acetaminophen limit 2 g/day in cirrhosis (not contraindicated)

— Avoid NSAIDs (variceal bleeding, hepatorenal)

— Tramadol and TCAs — reduce dose; risk of encephalopathy

— Vitamin K deficiency may reflect both cholestasis and malabsorption — give parenteral if INR elevated and bleeding

— Screen for HCC if cirrhosis present (US + AFP q6 months)

Step 3 management: In an elderly patient with CP starting pregabalin, adjust for renal function and screen for fall risk before discharge — failure to do so is a classic patient-safety distractor in vignettes.

Elderly patients:

Renal impairment:

Hepatic impairment (common in alcohol-related CP with concurrent cirrhosis):

Concurrent alcohol use disorder: avoid disulfiram in active CP (variable evidence; nausea exacerbates pain). Naltrexone safe in CP; acamprosate preferred if hepatic disease.

Special Populations — Pregnancy, Pediatrics, Genetic Disease

— CP in pregnancy is uncommon but rising; acute-on-chronic flares more common in 2nd/3rd trimester

— Imaging: MRI/MRCP without gadolinium preferred over CT

— Pain control: acetaminophen first; avoid NSAIDs after 20 weeks (premature ductal closure, oligohydramnios); short-course opioids acceptable but taper before delivery to avoid neonatal abstinence

— Pregabalin/gabapentin: limited data, weigh benefit vs. risk; avoid if possible

— PERT is safe in pregnancy (porcine origin, not absorbed systemically) — continue at usual doses

— Nutrition: maintain weight gain targets; supplement folate, iron, fat-soluble vitamins

— Alcohol and tobacco cessation imperative

— Almost always genetic or anatomic: PRSS1 (hereditary AD), CFTR (CF or CFTR-related), SPINK1, CTRC; pancreas divisum

— Refer for genetic counseling — implications for siblings, reproductive planning

— Hereditary pancreatitis (PRSS1) confers ~40% lifetime pancreatic cancer risk → annual EUS or MRI surveillance starting age 40 (or 20 years before youngest family case)

— TPIAT considered earlier in pediatric small-duct disease

— ~85% have pancreatic insufficiency at birth; remainder ("pancreatic sufficient") may develop CP later

— Higher PERT dosing required; CF-specific guidelines (lipase units/kg/meal: 500–2,500 U/kg, max 10,000 U/kg/day)

— All ages; type 1 older men, type 2 younger + IBD

— Prednisone 40 mg daily × 4 weeks, taper over 2–3 months; rituximab for relapse

— Reversible disease — don't miss it

Board pearl: A teenager with recurrent pancreatitis and a family history of early pancreatic cancer needs PRSS1 testing and surveillance enrollment — and the surveillance recommendation is annual MRI/EUS starting at age 40 (or 20 years before youngest affected relative).

Pregnancy:

Pediatric and young-adult CP:

Cystic fibrosis:

Autoimmune pancreatitis:

Complications and Adverse Outcomes

— Pseudocyst (>4 weeks old, encapsulated fluid): drain if symptomatic, infected, bleeding, or >6 cm and enlarging — EUS-guided transmural drainage preferred

— Walled-off necrosis: stepwise — antibiotics → percutaneous drain → endoscopic necrosectomy → surgery

— Pancreatic duct stricture with upstream dilation → ERCP stenting

— Biliary stricture (distal CBD compression): jaundice, pruritus, cholangitis → ERCP stent; surgical bypass if refractory

— Duodenal stenosis: gastric outlet obstruction → bypass

— Pancreatic ascites or pleural effusion: high-amylase fluid; treat with octreotide, drainage, ERCP stent across leak

— Splenic vein thrombosis → sinistral (left-sided) portal hypertension → isolated gastric varices → splenectomy if bleeding

— Pseudoaneurysm (splenic, GDA, hepatic): present with hemosuccus pancreaticus or sudden hemorrhage → angiographic embolization is first-line

— Portal/SMV thrombosis

— Type 3c diabetes: brittle, hypoglycemia-prone (glucagon also deficient); often insulin-requiring early

— Osteopenia/osteoporosis in up to 65% — DEXA every 2 years

— Sarcopenia, fat-soluble vitamin deficiency, B12 deficiency (loss of pancreatic protease cleavage of R-binder)

— Opioid dependence, depression (30–50%), disability, suicide risk

— Pancreatic adenocarcinoma — 4× baseline risk in CP; ~40% lifetime in hereditary CP. New constant pain, weight loss, or jaundice in stable CP → image immediately

Key distinction: Isolated gastric varices with normal liver function and a CP history = sinistral portal hypertension from splenic vein thrombosis; treatment is splenectomy, not the variceal banding/TIPS pathway used in cirrhotic portal hypertension.

Local/structural complications:

Vascular complications:

Metabolic/nutritional:

Pain/psychosocial:

Malignancy:

When to Escalate — ICU, Consult, Inpatient Triage

— Acute-on-chronic pancreatitis with persistent vomiting, inability to tolerate PO, dehydration, severe pain unresponsive to oral regimen

— SIRS criteria, hemodynamic instability, or organ failure → ICU

— Hemorrhage: hemosuccus pancreaticus (UGI bleed with CP) → IR-guided angiography/embolization, ICU

— Infected pseudocyst or walled-off necrosis: fever, leukocytosis, gas in collection → IV antibiotics (carbapenem), drainage

— Cholangitis: Charcot triad (fever, RUQ pain, jaundice) → urgent ERCP within 24–48 hours

— New-onset jaundice or palpable mass: admit/expedite imaging for malignancy

— Severe electrolyte derangement: refeeding hypophosphatemia, hypocalcemia with tetany

— Diabetic emergency: DKA rare but hypoglycemia common in type 3c → admit if recurrent

— IV fluids (LR 1.5–3 mL/kg/hr, goal UOP >0.5 mL/kg/hr)

— NPO initially, advance to clears as tolerated within 24 h (early enteral feeding reduces mortality)

— Multimodal analgesia: IV acetaminophen, IV ketorolac (if no contraindication), IV opioid PRN

— Antiemetics: ondansetron

— Continue home PERT once eating

— Hold home oral hypoglycemics; insulin sliding scale

— Treat precipitant: stop alcohol, image for stones/strictures/mass

— GI for any escalation, ERCP needs, drainage

— Surgery for pseudocyst >6 cm refractory to endotherapy, suspected malignancy, ductal anatomy amenable to drainage

— IR for hemorrhage, percutaneous drains

— Pain medicine, addiction medicine, nutrition, endocrinology, palliative care for chronic-disease management

CCS pearl: Early enteral nutrition (within 24–48 h) in acute-on-chronic pancreatitis improves outcomes vs. prolonged NPO — order a clear liquid diet as soon as pain and nausea allow, not "NPO until pain-free."

Outpatient management is the default; escalate when:

CCS-style management flow for acute-on-chronic flare:

Consultations:

Discharge readiness: tolerating PO, controlled pain on oral regimen, stable labs, follow-up booked.

Key Differentials — Pancreaticobiliary and Same-Category Causes

— Painless jaundice, rapid weight loss, new-onset diabetes >50, CA 19-9 markedly elevated

— Focal hypoattenuating mass on CT, ductal cutoff, double-duct sign

— EUS-FNA confirms; surveillance in hereditary CP

— Type 1: older men, elevated IgG4, sausage pancreas with rim, multiorgan IgG4 disease

— Type 2: younger, IBD-associated, normal IgG4

— Responds to steroids — completely changes management

— Gallstones (rule out with US even in known CP — coexistence common)

— Hypertriglyceridemia (>1000 mg/dL), hypercalcemia

— Drug-induced (azathioprine, valproate, GLP-1 agonists, DPP-4 inhibitors, didanosine)

— Anatomic: pancreas divisum, annular pancreas, sphincter of Oddi dysfunction

Key distinction: A diffusely enlarged "sausage" pancreas with rim enhancement in an older man with elevated IgG4 is autoimmune pancreatitis, not classic CP — give a trial of prednisone, don't refer for Whipple. Misdiagnosis as cancer leads to unnecessary pancreatectomy in 5–10% of cases historically.

Pancreatic adenocarcinoma — must always be excluded:

Autoimmune pancreatitis (AIP) — the don't-miss differential:

Recurrent acute pancreatitis — may be early CP or distinct etiology:

Choledocholithiasis/cholangitis: RUQ pain, jaundice, cholestatic LFTs, dilated CBD on US — overlaps with CP biliary stricture but typically acute

Sphincter of Oddi dysfunction: postcholecystectomy biliary-type pain with elevated LFTs/lipase; manometry historically, but high post-ERCP pancreatitis rate has limited intervention

Ampullary tumors and IPMN (intraductal papillary mucinous neoplasm): mimic CP with ductal dilation; main-duct IPMN has high malignant potential

Pancreatic neuroendocrine tumors: focal mass; functional tumors produce hormonal syndromes

Key Differentials — Other-Category Causes

Board pearl: A CP patient on chronic high-dose opioids with escalating diffuse abdominal pain despite dose increases likely has narcotic bowel syndrome / opioid-induced hyperalgesia — the answer is opioid taper with multimodal substitution, not further escalation. This is high-yield because the wrong answer (increase opioid) is the obvious distractor.

Peptic ulcer disease: epigastric pain, often relieved by food (DU) or worsened (GU); endoscopy diagnostic. Coexists with CP given shared risk factors (alcohol, tobacco)

Mesenteric ischemia (chronic): postprandial pain, "food fear," weight loss — overlaps clinically with CP. Look for vasculopathy, abdominal bruit; CTA/MRA mesenteric vessels

Gastroparesis: especially in diabetics; nausea, early satiety, postprandial bloating; gastric emptying study

Functional dyspepsia / IBS: diagnosis of exclusion; normal imaging and labs

Biliary disease: chronic cholecystitis, choledocholithiasis, primary sclerosing cholangitis (consider in IBD patient)

Celiac disease: steatorrhea, weight loss, fat-soluble vitamin deficiency — mimics exocrine insufficiency. Check tissue transglutaminase IgA; biopsy. May coexist with CP

Small intestinal bacterial overgrowth (SIBO): bloating, diarrhea, steatorrhea, B12 deficiency, often complicates CP after surgery or with dysmotility. Glucose or lactulose breath test; treat with rifaximin

Crohn disease: weight loss, diarrhea, malabsorption; ileal involvement → B12 and bile acid malabsorption

Adrenal insufficiency: vague abdominal pain, weight loss, hyperpigmentation, hyponatremia; cosyntropin stim

Hypercalcemia (hyperparathyroidism): can cause both pancreatitis and abdominal pain — check Ca²⁺, PTH

Opioid-induced bowel dysfunction or narcotic bowel syndrome: paradoxical worsening pain with escalating opioids — a key Step 3 trap in chronic CP

Secondary Prevention and Long-Term Plan

— Complete alcohol abstinence: refer to AA, formal addiction treatment; pharmacotherapy with naltrexone (or acamprosate if hepatic disease); document at every visit

— Tobacco cessation: varenicline 1st-line, NRT, bupropion; brief counseling at each visit (5 A's). Smoking accelerates calcification, pain progression, and cancer risk

— Address coexisting hypertriglyceridemia (<500 mg/dL goal), hypercalcemia

— PERT with each meal/snack; titrate to symptoms and weight

— PPI (omeprazole 20–40 mg) — adjunct to PERT and for GI prophylaxis

— Fat-soluble vitamins A, D, E, K; B12; calcium 1200 mg, vitamin D 1000–2000 IU

— Bisphosphonate if osteoporosis confirmed

— Diabetes therapy: metformin first if pancreatogenic DM with preserved function and no contraindication (lower cancer risk theoretically); insulin often needed; avoid sulfonylureas (hypoglycemia in glucagon-deficient patients)

— Pain regimen: maintain multimodal, minimize chronic opioids; reassess every 3 months

— Antidepressant if depression or as neuromodulator (duloxetine, nortriptyline)

— Hereditary CP (PRSS1, family history) → annual MRI ± EUS starting age 40 or 20 years before earliest family case

— Sporadic CP: surveillance not routinely recommended unless additional risk factors

Step 3 management: Build the discharge/clinic plan as PERT + PPI + vitamins + DM care + cessation Rx + vaccinations + DEXA + follow-up appointment — Step 3 vignettes reward the candidate who picks the bundle, not the single most "obvious" medication.

Etiologic prevention — the single biggest lever:

Long-term medication bundle:

Vaccinations: pneumococcal (PCV15/20 + PPSV23), influenza, hepatitis A/B (especially if alcohol-related), zoster, COVID; splenectomized patients also need meningococcal and Hib

Cancer surveillance:

Diabetes care bundle: HbA1c every 3–6 months, annual eye/foot/microalbumin, statin per ASCVD risk

Follow-Up, Monitoring, and Counseling

— Newly diagnosed/uncontrolled: every 4–8 weeks until stable

— Stable CP: every 3–6 months

— Diabetic patients: align with DM follow-up (every 3 months for HbA1c)

— Pain score, opioid use (PDMP check), functional status, mood (PHQ-9)

— Weight trend — single most informative outpatient metric for nutrition

— Stool pattern, steatorrhea symptoms

— Alcohol/tobacco status with documented counseling

— Medication review including PERT adherence and timing ("Do you take it with the first bite?")

— HbA1c every 3–6 months; fasting glucose annually if not yet diabetic

— Fat-soluble vitamins (A, D, E, INR), B12, magnesium, zinc, prealbumin annually

— DEXA at baseline, every 2 years

— CBC, CMP annually

— Cross-sectional imaging (MRI/MRCP) at baseline and if clinical change (new pain pattern, weight loss, jaundice); routine surveillance not standard except in hereditary CP

— Nutrition referral for individualized meal planning, small frequent moderate-fat meals

— Avoid prolonged fasting (triggers pain) and binge meals

— Behavioral pain therapy: CBT, mindfulness, acceptance/commitment therapy — evidence-based for chronic visceral pain

— Physical therapy for deconditioning and sarcopenia

— Addiction counseling and support groups

— Patient education: PERT timing, recognizing flare vs. complication, when to call

Key distinction: Weight gain and resolution of steatorrhea, not fecal elastase, is the right metric to track PERT response — fecal elastase reflects intrinsic pancreatic output and won't normalize with exogenous enzymes.

Visit cadence:

Monitoring parameters at each visit:

Periodic labs/imaging:

Rehabilitation and counseling:

Ethical, Legal, and Patient Safety Considerations

— Single-prescriber pain agreement with one pharmacy

— Check state PDMP before every refill; document

— Random urine drug screens

— Co-prescribe naloxone for patients on ≥50 MME/day or with concurrent benzodiazepines/alcohol use

— Avoid concurrent benzodiazepines; combination markedly increases overdose risk

— Document informed consent regarding dependence, tolerance, hyperalgesia

— Address opioid use disorder when present — buprenorphine is appropriate and effective; do not abandon the patient

— Avoid the moral framing ("self-inflicted"); CP is a chronic disease deserving the same management discipline as CHF or COPD

— Ongoing alcohol use is not grounds to withhold standard care, including PERT, pain control, or transplant evaluation in selected cases (with sobriety requirements per program)

— ERCP in CP: high (~5–10%) post-procedure pancreatitis risk — must be explicitly discussed

— TPIAT: lifelong brittle diabetes is the consent counterpoint

— Surveillance imaging in hereditary CP: discuss psychological burden and incidental findings

— Hospital discharge after acute-on-chronic flare is the highest-risk transition: ensure PERT is on the discharge med list, opioid taper plan is explicit, follow-up booked in 1–2 weeks, PCP and GI notified

— Medication reconciliation must catch missed PERT (often omitted from hospital formularies) and inappropriate continuation of inpatient opioids

— Impaired driving from opioids/sedatives — state-specific reporting requirements for some clinicians

— Concerns about diversion → document and address

Step 3 management: Before discharging a CP patient on chronic opioids, co-prescribe naloxone, run the PDMP, confirm one-prescriber/one-pharmacy, and book follow-up within 1–2 weeks — these are the discrete, testable safety actions Step 3 rewards.

Opioid prescribing safety — the dominant Step 3 ethics-safety domain in CP:

Stigma and the alcohol-using patient:

Informed consent edge cases:

Transition-of-care risks:

Mandatory reporting:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When a CP vignette gives you steatorrhea despite PERT, the next-step ladder is always: (1) confirm timing with meals → (2) increase the dose → (3) add a PPI → (4) work up SIBO.

Top causes (US adults): alcohol > idiopathic > tobacco (independent) > genetic > autoimmune > obstructive

Fecal elastase-1 <100 μg/g = severe exocrine insufficiency; unaffected by exogenous PERT

PERT dosing: 40,000–50,000 lipase units with meals, half with snacks, with first bite

Failed PERT → first increase dose, then add PPI, then evaluate for SIBO

Calcifications on imaging are pathognomonic but late — absence does NOT exclude CP

EUS is most sensitive for early/small-duct CP

Secretin-MRCP evaluates ductal compliance and exocrine reserve noninvasively

Pregabalin has the best RCT evidence for CP pain among neuromodulators

Tramadol > traditional opioids: equal analgesia, less constipation

Splenic vein thrombosis → isolated gastric varices → splenectomy if bleeding

Hemosuccus pancreaticus → pseudoaneurysm → angiographic embolization

Type 3c (pancreatogenic) diabetes: insulin AND glucagon deficient → brittle, hypoglycemia-prone; avoid sulfonylureas

Hereditary CP (PRSS1): ~40% lifetime pancreatic cancer; annual MRI/EUS surveillance from age 40

Autoimmune pancreatitis: sausage pancreas + IgG4 elevation + multiorgan IgG4 disease → prednisone, dramatic response

TPIAT for diffuse small-duct CP refractory pain — preserves some islet function

Dilated main duct (>6–7 mm) → endoscopic stenting first, surgical drainage (Puestow, Frey) if fails

ESCAPE trial: earlier surgery > step-up endotherapy for pain in selected patients

Fat-soluble vitamin deficiency consequences: night blindness (A), osteomalacia (D), neuropathy (E), bleeding (K)

Smoking cessation is independently the most disease-modifying intervention along with alcohol abstinence

Narcotic bowel syndrome = paradoxical pain with escalating opioids → taper, not escalate

Board Question Stem Patterns

Step 3 management: When you see "CP + ___", quickly map it to one of these 10 stem patterns — the right answer almost always lives in the bundle response (lifestyle + targeted Rx + appropriate referral + safety net), not a single drug.

The "alcohol + epigastric pain + calcifications" classic: 45-year-old man with heavy alcohol use, recurrent epigastric pain radiating to back, weight loss; CT shows pancreatic calcifications and ductal dilation. → Diagnosis is CP; next step is fecal elastase-1 (functional confirmation) and alcohol/tobacco cessation counseling.

The "steatorrhea despite enzymes" stem: Patient on PERT still has greasy stools. → Best next step is increase PERT dose; if already maximal, add a PPI; persistent symptoms → workup for SIBO.

The "young patient with recurrent pancreatitis": Adolescent with multiple episodes, family history of pancreatic cancer. → Order PRSS1 genetic testing; plan surveillance from age 40.

The "AIP masquerade": 65-year-old man with painless jaundice, diffusely enlarged "sausage" pancreas, elevated IgG4, retroperitoneal fibrosis. → Prednisone 40 mg/day, not Whipple.

The "isolated gastric varices" stem: CP patient with UGI bleed; endoscopy shows gastric varices only, normal LFTs. → Splenic vein thrombosis with sinistral portal hypertension → splenectomy.

The "new-onset diabetes + weight loss": Thin 60-year-old develops diabetes and weight loss, then back pain. → Image for pancreatic adenocarcinoma; CT pancreas protocol, then EUS-FNA if mass.

The "opioid escalation trap": CP patient on high-dose opioids with worsening pain despite dose increases. → Narcotic bowel syndrome / hyperalgesia; answer is opioid taper + multimodal therapy (pregabalin, duloxetine, CBT).

The "post-discharge safety" stem: CP patient discharged on opioids and PERT. → Best next step is naloxone Rx, PDMP check, follow-up within 1–2 weeks.

The "early CP" stem: Patient with chronic epigastric pain, normal CT and MRCP. → Best next test is endoscopic ultrasound.

The "dilated duct" surgical stem: CP with main duct >7 mm, refractory pain despite endotherapy. → Lateral pancreaticojejunostomy (Puestow).

One-Line Recap

Chronic pancreatitis is a progressive, irreversible fibroinflammatory disease whose lifelong management rests on four parallel tracks — etiologic modification (alcohol and tobacco cessation above all), multimodal opioid-sparing pain control, pancreatic enzyme replacement with fat-soluble vitamin support, and pancreatogenic diabetes care — layered with vigilance for pseudocysts, splenic vein thrombosis, biliary strictures, and pancreatic adenocarcinoma.

Board pearl: The Step 3 right answer in CP is almost always a longitudinal management bundle — cessation counseling, PERT, vitamins, diabetes screening, vaccinations, DEXA, opioid safety, and a scheduled follow-up — not a single magic drug. Treat CP like CHF: a chronic disease with a checklist, not a single-symptom complaint.

Diagnosis: Combine clinical phenotype with imaging (CT first → MRCP → EUS for early/small-duct disease) and a fecal elastase-1 for exocrine function. Don't forget IgG4 to exclude autoimmune pancreatitis — a steroid-responsive mimic.

Pain ladder: acetaminophen → pregabalin/duloxetine → tramadol → short-acting opioids (with PDMP, naloxone, single-prescriber agreement). Escalating pain on opioids = consider narcotic bowel syndrome; taper, don't escalate.

Exocrine insufficiency: PERT 40,000–50,000 units with each meal, with the first bite; add PPI if inadequate; track weight and steatorrhea, not fecal elastase, for response.

Don't miss: pancreatic adenocarcinoma (new mass, weight loss, jaundice → EUS-FNA), hereditary CP surveillance (annual MRI/EUS from age 40 in PRSS1), and the isolated gastric varices → splenectomy vignette.